SLC5A2 and heart failure: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are perhaps the most powerful pharmaceutical advancement to date in the treatment of heart failure (HF), which makes the serendipitous identification of the cardiovascular benefit of these drugs originally intended to treat diabetes all the more notable.